Wells Fargo Maintains Bruker Corp(BRKR.US) With Buy Rating, Maintains Target Price $78
Bruker Announces One-Hundred Dollar, Deep, High-Accuracy Plasma Proteome; Advances Glycoproteomics and Metaproteomics
BRKR Stock to Gain From Newly Formed Bruker Spatial Biology Division
European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics Against NanoString's CosMx SMI Products
Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress
Investors Appear Satisfied With Bruker Corporation's (NASDAQ:BRKR) Prospects